// App-Quantinova.ai

5025 : Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Scott T. Tagawa

Principal Investigators

  • Edwin M. Posadas

  • Weimin Peng

  • Raymond Scott Maul

  • Hans W. Smit

  • Namphuong Tran

  • David M. Nanus

Medical Centers

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • University of Wisconsin, School of Medicine and Public Health, Madison, WIJanssen Research and Development, Los Angeles, CAWeill Cornell Medical College, New York, NY

  • Janssen Research & Development, Beerse, Belgium

  • Yale Cancer Center, New Haven, CT

  • Columbia University Medical Center, New York, NY

Locations

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Thrombocytopenia

  • Prostate cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • Indeterminate

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01400555

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved